<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, Feb. 24, 2020 (HealthDay News) — Daily emollient during the first year of life does not prevent eczema in high-risk children, according to a study published online Feb. 19 in The Lancet<\/i>.<\/p>\n
Joanne R. Chalmers, Ph.D., from the University of Nottingham in the United Kingdom, and colleagues tested whether daily use of emollient in the first year could prevent eczema in high-risk children. Term newborns with a family history of atopic disease were randomly assigned (1:1) to either daily emollient (either Diprobase cream or DoubleBase gel) plus standard skin-care advice (emollient group; 693 infants) or standard skin-care advice only (control group; 701 infants) for one year.<\/p>\n
Adherence in the emollient group was 88 percent at 3 months of age, 82 percent at 6 months, and 74 percent at 12 months. The researchers found that eczema was present in 23 percent of infants in the emollient group with two-year follow-up data and in 25 percent of infants in the control group (adjusted relative risk, 0.95; 95 percent confidence interval, 0.78 to 1.16; P = 0.61). In year 1, the mean number of skin infections per child was 0.23 in the emollient group versus 0.15 in the control group (adjusted incidence rate ratio, 1.55; 95 percent confidence interval, 1.15 to 2.09).<\/p>\n
“Our study shows that families with eczema, asthma, or allergic rhinitis should not use daily emollients to try and prevent eczema in their newborn,” conclude the authors.<\/p>\n
Several authors disclosed financial ties to the pharmaceutical industry.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n